PBSV — Pharma-Bio Serv Income Statement
0.000.00%
Last trade - 00:00- $12.83m
- $1.97m
- $9.00m
- 70
- 58
- 23
- 50
Annual income statement for Pharma-Bio Serv, fiscal year end - October 31st, USD millions except per share, conversion factor applied.
2021 October 31st | 2022 October 31st | 2023 October 31st | 2024 October 31st | 2025 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 20.1 | 19.4 | 17 | 9.51 | 9 |
| Cost of Revenue | |||||
| Gross Profit | 5.36 | 4.88 | 5.07 | 2.52 | 2.91 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 22 | 18.2 | 15.9 | 10.8 | 9.64 |
| Operating Profit | -1.9 | 1.17 | 1.12 | -1.29 | -0.638 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.88 | 1.19 | 1.69 | -0.755 | -0.094 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.09 | 1.01 | 1.31 | -0.778 | -0.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.09 | 1.01 | 1.31 | -0.778 | -0.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.09 | 1.01 | 1.31 | -0.778 | -0.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.146 | 0.044 | 0.057 | -0.034 | -0.004 |
| Special Dividends per Share |